BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Misawa K, Misawa Y, Kanazawa T, Mochizuki D, Imai A, Endo S, Carey TE, Mineta H. Epigenetic inactivation of galanin and GALR1/2 is associated with early recurrence in head and neck cancer. Clin Exp Metastasis 2016;33:187-95. [PMID: 26572146 DOI: 10.1007/s10585-015-9768-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Kiezun J, Kiezun M, Krazinski BE, Paukszto L, Koprowicz-wielguszewska A, Kmiec Z, Godlewski J. Galanin Receptors (GALR1, GALR2, and GALR3) Immunoexpression in Enteric Plexuses of Colorectal Cancer Patients: Correlation with the Clinico-Pathological Parameters. Biomolecules 2022;12:1769. [DOI: 10.3390/biom12121769] [Reference Citation Analysis]
2 Wang J, Yang Z, Liu Y, Li H, Yang X, Gao W, Zhao Q, Yang X, Wei J. The GAL/GALR2 axis promotes the perineural invasion of salivary adenoid cystic carcinoma via epithelial-to-mesenchymal transition. Cancer Med 2022. [PMID: 36039037 DOI: 10.1002/cam4.5181] [Reference Citation Analysis]
3 Sánchez ML, Coveñas R. The Galaninergic System: A Target for Cancer Treatment. Cancers 2022;14:3755. [DOI: 10.3390/cancers14153755] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Gu S, Qian S, Lin S, Ye D, Li Q, Yang J, Ying X, Li Z, Tang M, Wang J, Chen K, Jin M. Promoter hypermethylation of GALR1 acts as an early epigenetic susceptibility event in colorectal carcinogenesis. J Hum Genet 2022. [PMID: 35606503 DOI: 10.1038/s10038-022-01038-9] [Reference Citation Analysis]
5 Kiezun J, Godlewski J, Krazinski BE, Kozielec Z, Kmiec Z. Galanin Receptors (GalR1, GalR2, and GalR3) Expression in Colorectal Cancer Tissue and Correlations to the Overall Survival and Poor Prognosis of CRC Patients. Int J Mol Sci 2022;23:3735. [PMID: 35409094 DOI: 10.3390/ijms23073735] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Sorroche BP, Talukdar FR, Lima SCS, Melendez ME, de Carvalho AC, de Almeida GC, De Marchi P, Lopes M, Ribeiro Pinto LF, Carvalho AL, Herceg Z, Arantes LMRB. DNA Methylation Markers from Negative Surgical Margins Can Predict Recurrence of Oral Squamous Cell Carcinoma. Cancers (Basel) 2021;13:2915. [PMID: 34207933 DOI: 10.3390/cancers13122915] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
7 Misawa K, Misawa Y, Mima M, Yamada S, Imai A, Mochizuki D, Nakagawa T, Kurokawa T, Endo S, Kawasaki H, Brenner JC, Mineta H. Overexpression of Sal-like protein 4 in head and neck cancer: epigenetic effects and clinical correlations. Cell Oncol (Dordr) 2020;43:631-41. [PMID: 32240499 DOI: 10.1007/s13402-020-00509-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Misawa K, Yamada S, Mima M, Nakagawa T, Kurokawa T, Imai A, Mochizuki D, Morita K, Ishikawa R, Endo S, Misawa Y. 5-Hydroxymethylcytosine and ten-eleven translocation dioxygenases in head and neck carcinoma. J Cancer 2019;10:5306-14. [PMID: 31602281 DOI: 10.7150/jca.34806] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
9 Wei Q, Ramsey SA, Larson MK, Berlow NE, Ochola D, Shiprack C, Kashyap A, Séguin B, Keller C, Löhr CV. Elucidating the transcriptional program of feline injection-site sarcoma using a cross-species mRNA-sequencing approach. BMC Cancer 2019;19:311. [PMID: 30947707 DOI: 10.1186/s12885-019-5501-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
10 Kanazawa T, Misawa K, Shinmura K, Misawa Y, Kusaka G, Maruta M, Sasaki T, Watanabe Y, Carey TE. Promoter methylation of galanin receptors as epigenetic biomarkers for head and neck squamous cell carcinomas. Expert Rev Mol Diagn 2019;19:137-48. [PMID: 30640567 DOI: 10.1080/14737159.2019.1567334] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
11 Russo D, Merolla F, Varricchio S, Salzano G, Zarrilli G, Mascolo M, Strazzullo V, Di Crescenzo RM, Celetti A, Ilardi G. Epigenetics of oral and oropharyngeal cancers. Biomed Rep 2018;9:275-83. [PMID: 30233779 DOI: 10.3892/br.2018.1136] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
12 Kanazawa T, Misawa K, Fukushima H, Misawa Y, Sato Y, Maruta M, Imayoshi S, Kusaka G, Kawabata K, Mineta H, Carey TE, Nishino H. Epigenetic inactivation of galanin receptors in salivary duct carcinoma of the parotid gland: Potential utility as biomarkers for prognosis. Oncol Lett 2018;15:9043-50. [PMID: 29805635 DOI: 10.3892/ol.2018.8525] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
13 Thunders M, Chinn V, Bilewitch J, Stockwell P. Identification of potential 'lifestyle-responsive' epigenomic biomarkers in healthy women aged 18-40. Biomarkers 2018;23:453-61. [PMID: 29460649 DOI: 10.1080/1354750X.2018.1443512] [Reference Citation Analysis]
14 Yoon D, Bae K, Lee MK, Kim JH, Yoon KA. Galanin is an epigenetically silenced tumor suppressor gene in gastric cancer cells. PLoS One 2018;13:e0193275. [PMID: 29462183 DOI: 10.1371/journal.pone.0193275] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
15 Ribeiro IP, Marques F, Barroso L, Miguéis J, Caramelo F, Santos A, Julião MJ, Melo JB, Carreira IM. Genetic and epigenetic characterization of the tumors in a patient with a tongue primary tumor, a recurrence and a pharyngoesophageal second primary tumor. Mol Cytogenet 2017;10:13. [PMID: 28413448 DOI: 10.1186/s13039-017-0310-z] [Reference Citation Analysis]
16 Barde S, Rüegg J, Prud'homme J, Ekström TJ, Palkovits M, Turecki G, Bagdy G, Ihnatko R, Theodorsson E, Juhasz G, Diaz-Heijtz R, Mechawar N, Hökfelt TG. Alterations in the neuropeptide galanin system in major depressive disorder involve levels of transcripts, methylation, and peptide. Proc Natl Acad Sci U S A 2016;113:E8472-81. [PMID: 27940914 DOI: 10.1073/pnas.1617824113] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 5.7] [Reference Citation Analysis]
17 Galoian K, Patel P. Epigenetic control of cancer by neuropeptides. Biomed Rep 2017;6:3-7. [PMID: 28123699 DOI: 10.3892/br.2016.804] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
18 Misawa K, Mochizuki D, Endo S, Mima M, Misawa Y, Imai A, Shinmura K, Kanazawa T, Carey TE, Mineta H. Site-specific methylation patterns of the GAL and GALR1/2 genes in head and neck cancer: Potential utility as biomarkers for prognosis: METHYLATION PATTERNS OF THE GAL AND GALR1/2 GENES. Mol Carcinog 2017;56:1107-16. [DOI: 10.1002/mc.22577] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
19 Lim AM, Wong NC, Pidsley R, Zotenko E, Corry J, Dobrovic A, Clark SJ, Rischin D, Solomon B. Genome-scale methylation assessment did not identify prognostic biomarkers in oral tongue carcinomas. Clin Epigenetics 2016;8:74. [PMID: 27433284 DOI: 10.1186/s13148-016-0235-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]